THE SIGNIFICANCE OF INFLAMMATION IN PATHOGENESIS, DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS
Abstract
Atherosclerosis is a chronic disease whose progression starts from birth. The basic substrate of an atherosclerotic lesion is the deposition of lipids in the intima of the blood vessel, which results in gradual narrowing and impaired blood flow through the tissues. The clinical manifestations of the atherosclerotic process are numerous and they depend on the degree of narrowing and the speed of the stenosis. The most common clinical manifestations are the result of rupture of the atherosclerotic plaque, which activates the process of thrombogenesis and leads to the development of blockage of blood vessels. The most important risk factors for atherosclerosis are elevated LDL, decreased HDL, cigarette use, hypertension, type II diabetes mellitus, age, family history of cardiovascular disease in first-line relatives (men younger than 55 years, women younger than 65 years). . When mild forms of atherosclerosis are observed, they generally do not have any symptoms. And with advanced atherosclerosis, there are visible and noticeable symptoms that vary depending on which artery it affects. Some of them are: chest pain - caused by atherosclerosis in the arteries of the heart, acute brain ischemia or stroke - caused by atherosclerosis in the arteries leading to the brain, difficulty walking - narrowed arteries in the legs, high blood pressure, kidney failure, erectile dysfunction in men and painful relations in women - atherosclerosis in the arteries of the genital tract. The aim of this paper is to adequately investigate and show the connection between inflammation and atherosclerosis.
References
2. Wilcox J, Smith K, Schwatrz S, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 1989; 86: 2839 – 2843.
3. Ross R, Glomset J. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973; 180: 1332 – 1339.
4. Williams K, Tabas I. The response-to-retention hypothesis of early atherosclerosis. Arterioscl Thromb Vasc Biol. 1995; 15: 551 – 561.
5. Williams K, Tabas I. The response-to-retention hypothesis of atherosclerosis reinforced. Curr Opin Lipidol. 1998; 9: 471 – 474.
6. Goldstein J, Ho Y, Basu S, Brown M. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 1979; 76: 333 -337.
7. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 2010; 10:36–46. doi: 10.1038/nri2675.
8. Calabro P, Willerson J.T, Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation, 2003; 108: 1930-1932.
9. Björkegren JLM, Lusis AJ. Atherosclerosis: Recent developments. Cell. 2022 May 12;185(10):1630-1645. doi: 10.1016/j.cell.2022.04.004.
10. Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001; 103: 2531–2534.
11. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115-26. doi: 10.1056/NEJM199901143400207
12. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation, 2003; 107: 363-369.
13. Barbu E; Popescu MR, Popescu AC, Balanescu SM. Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging. Int. J. Mol. Sci. 2022, 23, 963. https://doi.org /10.3390/ijms23020963
14. Witztum JL, Berliner JA. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol. 1998; 9: 441–448.
15. Kotlyarov S.; Kotlyarova A.Involvement of Fatty Acids and Their Metabolites in the Development of Inflammation in Atherosclerosis. Int. J. Mol. Sci. 2022, 23, 1308. https://doi.org/10.3390/ijms23031308
16. Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022 Apr 22;7(1):131. doi: 10.1038/s41392-022-00955-7.
17. Björkegren JLM, Lusis AJ. Atherosclerosis: Recent developments. Cell. 2022 May 12;185(10):1630-1645. doi: 10.1016/j.cell.2022.04.004.
18. Bakić M, Patogenetski aspekti ateroskleroze, Acta Medica Medianae 2007;46(1):25-29.
19. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull Jr W, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995 Sep 1;92(5):1355-74..
20. Meng H, Ruan J, Yan Z, Chen Y, Liu J, Li X, et al. New Progress in Early Diagnosis of Atherosclerosis. Int. J. Mol. Sci. 2022, 23, 8939. https://doi.org/10.3390/ijms23168939
21. Adam CA, Șalaru DL, Prisacariu C, Marcu DTM, Sascău RA, Stătescu C. Novel Biomarkers of Atherosclerotic Vascular Disease—Latest Insights in the Research Field. Int. J. Mol. Sci. 2022, 23, 4998. https://doi.org/10.3390/ijms23094998
22. Cao H, Zhu Y, Hu G, Zhang Q, Zheng L. Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis? Pharmacological Research. 2023 Jan;187:106586. DOI: 10.1016/j.phrs.2022.106586
23. Libby P. Inflammation in atherosclerosis—no longer a theory. Clinical chemistry. 2021 Jan;67(1):131-42.